NewLead Holdings Ltd (NASDAQ:NEWL), announced that its Annual Report on Form 20-F for the fiscal year ended December 31, 2013 (the “Annual Report”) has been filed with the U.S. Securities and Exchange Commission. NewLead Holdings Ltd (NASDAQ:NEWL), weekly performance is 13.61%. On last trading day company shares ended up $-72.50. NewLead Holdings Ltd (NASDAQ:NEWL), distance from 50-day simple moving average (SMA50) is -98.40%.
On May 12, 2014, Zulily Inc (NASDAQ:ZU), posted the unanticipated loss for the Q1 2014 financial year that ended 30 March 30, 2014, despite the fact that its revenues increased very significantly in the quarter. Any positivity that had been generated by strong growth in revenues were negated by the surprise loss, & investors punished the ZU stock, pushing it down by 7.82 % to close at $30.42 in Fridays trading session. Zulily Inc (NASDAQ:ZU), advanced 9.31% in last trading session and ended the day on $34.99. ZU, Gross Margin is 27.30% and its return on assets is -1.10%. Zulily Inc (NASDAQ:ZU), quarterly performance is -11.75%.
Enzymotec Ltd (NASDAQ:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, reported financial results for the first quarter ended March 31, 2014. Net Revenues Increased 29% to $17.9 Million. Net Income Increased 118% to $5.1 Million, or $0.22 Per Share. Quarterly Non-GAAP Net Income Increased 135% to $5.6 Million, or $0.24 Per Share. Enzymotec Ltd (NASDAQ:ENZY), shares moved down 32.03% in last trading session and was closed at $13.75, while trading in range of $13.60 – 18.46. Enzymotec Ltd (NASDAQ:ENZY), year to date (YTD) performance is -49.09%.
MELA Sciences Inc (NASDAQ:MELA), developer of the MelaFind system, an optical diagnostic device approved for use in the United States and the European Union to assist dermatologists in melanoma diagnosis, announced results for its fiscal 2014 first quarter (Q1’14) ended March 31, 2014. MELA Sciences reported a Q1’14 net loss of approximately $8.0 million, or $0.16 per share, compared with a net loss of approximately $6.5 million, or $0.17 per share for the comparable period last year. Included in the Q1’14 financial results were liquidated damages of approximately $3.4 million incurred and paid in connection with the Company’s financing completed in February 2014. MELA Sciences Inc (NASDAQ:MELA), ended the last trading day at $0.444. Company weekly volatility is calculated as 8.38% and price to cash ratio as 6.08. MELA Sciences Inc (NASDAQ:MELA), showed a negative weekly performance of 11.22%.
Leave a Reply